Regeneron Pharmaceuticals, Inc. (Regeneron); Pfizer, Inc. (Pfizer); and BioNTech SE and BioNTech US, Inc. (collectively BioNTech) for allegedly infringing U.S. Patent No. 10,221,221 (the ’221 patent),
The ‘221 Patent
The ’221 patent, titled “Monomeric Yellow-Green Fluorescent Protein from Cephalochordate,” was assigned to Allele and directed to high performance monomeric yellow-green fluorescent proteins. Although mNeonGreen was “Allele’s breakthrough in fluorescent protein technology,” Allele has many other achievements, including advances in “RNA interference, Fluorescent Proteins, Induced Pluripotent Stem Cells (iPSCs), Genome Editing, and camelid derived Single Domain Antibodies.” Most recently, Allele has also been “actively engaged in combating COVID-19, initiating impactful diagnostic and therapeutic platforms premised on speed, accuracy, and sensitivity.” Allele’s mNeonGreen technology has been licensed to hundreds of organizations and universities. As asserted by Allele, mNeonGreen “facilitates quick, targeted, and precise receptor research, including for potential therapeutics to treat COVID-19.”
The ’221 patent, titled “Monomeric Yellow-Green Fluorescent Protein from Cephalochordate,” was assigned to Allele and directed to high performance monomeric yellow-green fluorescent proteins. Although mNeonGreen was “Allele’s breakthrough in fluorescent protein technology,” Allele has many other achievements, including advances in “RNA interference, Fluorescent Proteins, Induced Pluripotent Stem Cells (iPSCs), Genome Editing, and camelid derived Single Domain Antibodies.” Most recently, Allele has also been “actively engaged in combating COVID-19, initiating impactful diagnostic and therapeutic platforms premised on speed, accuracy, and sensitivity.” Allele’s mNeonGreen technology has been licensed to hundreds of organizations and universities. As asserted by Allele, mNeonGreen “facilitates quick, targeted, and precise receptor research, including for potential therapeutics to treat COVID-19.”
However, the high court found that complimentary DNA — known as cDNA — "is not a 'product of nature' and is patent eligible under (the law)."
The specific patent of SARS-CoV featured in "Plandemic II" — "Coronavirus isolated from humans," Patent #7,220,852 B1 — includes the "isolated coronavirus genome, isolated coronavirus proteins, and isolated nucleic acid molecules." About 20 pages of the patent describe the process of isolating the genome, including the synthesis of cDNA.
Experts also noted that other steps in the process — like stripping genetic material from its chromosome and creating copies, or the use of biotechnology in general — likely made the patent viable.
The specific patent of SARS-CoV featured in "Plandemic II" — "Coronavirus isolated from humans," Patent #7,220,852 B1 — includes the "isolated coronavirus genome, isolated coronavirus proteins, and isolated nucleic acid molecules." About 20 pages of the patent describe the process of isolating the genome, including the synthesis of cDNA.
Experts also noted that other steps in the process — like stripping genetic material from its chromosome and creating copies, or the use of biotechnology in general — likely made the patent viable.
Please open Telegram to view this post
VIEW IN TELEGRAM